Harrow (NASDAQ:HROW) Given Buy Rating at HC Wainwright

Harrow (NASDAQ:HROW)‘s stock had its “buy” rating reaffirmed by analysts at HC Wainwright in a research report issued on Tuesday,Benzinga reports. They presently have a $57.00 price target on the stock. HC Wainwright’s price target suggests a potential upside of 115.11% from the stock’s current price.

Separately, B. Riley dropped their target price on shares of Harrow from $73.00 to $69.00 and set a “buy” rating on the stock in a report on Wednesday, December 4th.

Harrow Trading Up 13.6 %

Shares of NASDAQ:HROW traded up $3.18 during trading on Tuesday, reaching $26.50. 1,399,188 shares of the company were exchanged, compared to its average volume of 385,732. The business’s fifty day simple moving average is $30.19 and its 200-day simple moving average is $38.73. The company has a debt-to-equity ratio of 3.23, a current ratio of 1.55 and a quick ratio of 1.44. Harrow has a 12-month low of $9.30 and a 12-month high of $59.23. The firm has a market capitalization of $943.73 million, a PE ratio of -28.11 and a beta of 0.69.

Institutional Trading of Harrow

A number of institutional investors have recently modified their holdings of HROW. JPMorgan Chase & Co. lifted its position in Harrow by 443.1% during the third quarter. JPMorgan Chase & Co. now owns 238,367 shares of the company’s stock valued at $10,717,000 after acquiring an additional 194,480 shares during the last quarter. Oppenheimer & Co. Inc. purchased a new stake in shares of Harrow during the 3rd quarter valued at $1,267,000. Penserra Capital Management LLC purchased a new position in Harrow during the 3rd quarter worth $1,986,000. Barclays PLC increased its position in Harrow by 301.9% during the 3rd quarter. Barclays PLC now owns 52,593 shares of the company’s stock valued at $2,365,000 after buying an additional 39,506 shares in the last quarter. Finally, First Turn Management LLC purchased a new stake in Harrow in the third quarter valued at about $14,683,000. 72.76% of the stock is currently owned by institutional investors.

Harrow Company Profile

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.